Drugs / IBI333
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05639530 | Feb → Dec 2023 | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-02-28 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05639530 ↗ |
| Route | Intravitreal | “Intravitreal injection of IBI333” NCT05639530 ↗ |